Unpicking the combination lock for mutant BRAF and RAS melanomas
- PMID: 23319765
- DOI: 10.1158/2159-8290.CD-12-0520
Unpicking the combination lock for mutant BRAF and RAS melanomas
Abstract
Large-scale, unbiased combinatorial drug screening has been used to identify effective genotype-selective therapeutic combinations that show promising activity in preclinical models of mutant BRAF andRAS melanoma that are resistant to the clinical BRAF inhibitor vemurafenib.
Comment on
-
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening.Cancer Discov. 2013 Jan;3(1):52-67. doi: 10.1158/2159-8290.CD-12-0408. Epub 2012 Dec 13. Cancer Discov. 2013. PMID: 23239741 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
